For US Healthcare Professionals
For US Healthcare Professionals
IN ADULTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
POOLED DATA FROM DISCOVER 1 AND DISCOVER 2: RESOLUTION OF ENTHESITIS (LEI SCORE=0) AT WEEK 24 (NRI ANALYSIS)*†‡
ENTHESITIS
*Among patients with enthesitis (Leeds Enthesitis Index [LEI]) at baseline.
†Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
‡Patients with missing data were considered nonresponders.
POOLED DATA FROM DISCOVER 1 AND DISCOVER 2: RESOLUTION OF DACTYLITIS (DACTYLITIS SCORE=0) AT WEEK 24 (NRI ANALYSIS)||¶#
DACTYLITIS
||Among patients with dactylitis at baseline.
¶Through Week 24, patients were considered to be nonresponders after meeting treatment failure criteria: discontinued study agent due to any reason, terminated study participation for any reason, initiated or increased the dose of DMARDs or oral corticosteroids over baseline for PsA, or initiated protocol-prohibited medications/therapies for PsA. After Week 24, treatment failure rules were not applied.
#Patients with missing data were considered nonresponders.
Reference: 1. Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER 2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;20(30263):1-11.